Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for
treating patients with the diagnosis of advanced Non-Small-Lung-Cancer